US4983393A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Intra-vaginal device and method for sustained drug release
Assignee: BELMAC/MAXIMED PARTNERSHIP
•
Filing: 1988-10-14
•
Granted: 1991-01-08
•
Expires: 2008-10-14
Abstract
Abstract The invention disclosed provides an intra-vaginal device prepared using ingredients which slowly release in the vagina over a significant period of time. The present intra-vaginal device also usefully serves as a drug release means for controllably releasing a drug in the vagina. A method for controlled drug release in the vagina is also disclosed.
Inventors
- 👤 Robert S. Cohen
- 👤 James M. Pierce
- 👤 William H. Kinsey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 14:34
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0034
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
131 words
A solid, shaped, integral, solidified composition suitable for use as an intra-vaginal insert and capable of dissolution or disintegration in the presence of vaginal fluids, comprising agarose in an amount from about 0.1% to about 4% by weight, agar in that amount of about 0.1% to about 4% by weight, saline solution, high molecular weight glycosaminoglycans of about 100,000 Daltons to about 1,000,000 Daltons in an amount from about 0.1% to about 20% by weight, collagen in an amount from about 0.1% to about 20% by weight, fibrin in an amount from about 0.1% to about 20% by weight and an enzyme selected from the group consisting of agarase, protease, collagenase and saccharidase, said enzyme being present in said composition in an amount from about 0% to about 10% by weight.
Claim 2
Dependent Claim
131 words
A solid, shaped, integral, solidified composition suitable for use as an intra-vaginal insert and capable of dissolution or disintegration in the presence of vaginal fluids, comprising agarose in an amount from about 0.1% to about 4% by weight, agar in that amount of about 0.1% to about 4% by weight, saline solution, high molecular weight glycosaminoglycans of about 100,000 Daltons to about 1,000,000 Daltons in an amount from about 0.1% to about 20% by weight, collagen in an amount from about 0.1% to about 20% by weight, fibrin in an amount from about 0.1% to about 20% by weight and an enzyme selected from the group consisting of agarase, protease, collagenase and saccharidase, said enzyme being present in said composition in an amount from about 0% to about 10% by weight.
Claim 3
Dependent Claim
13 words
A composition in accordance with claim 1 wherein said composition contains a spermicide.
Claim 4
Dependent Claim
13 words
A composition in accordance with claim 1 wherein said composition contains a germicide.
Claim 5
Dependent Claim
13 words
A composition in accordance with claim 1 wherein said composition contains a viricide.
Claim 6
Dependent Claim
31 words
A method for the sustained intra-vaginal release of a drug which comprises incorporating said drug in a composition in accordance with claim 1 and inserting the resulting composition into the vagina.
References Cited (Backward Citations)
US2110962A
Cited
US3429308A
Cited
US3432594A
Cited
US4274410A
Cited
US4381772A
Cited
US4468465A
Cited
US4703108A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-07 | 1994-07-09 | 1995-01-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-07 | 1998-07-09 | 1999-01-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-07 | 2002-07-09 | 2003-01-08 | $7700.00 | Window Closed / Lapsed |